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Abstract. Discrepancies in the response to drugs are partially 
due to polymorphisms in genes involved in drug metabolism 
and transport. The frequency, pattern and impact of these 
polymorphisms vary among populations. In the present 
study, the pharmacokinetics and pharmacogenetics of ator-
vastatin (ATV) in a Mexican population were investigated. 
The study cohort exhibited differing ATV metabolizing 
phenotypes, and in subsequent allelic discrimination assays, 
single nucleotide polymorphisms in the angiotensinogen, 
angiotensin II type 1 receptor (AGTR1) and bradykinin B2 
receptor (BDKRB2) genes were genotyped and their effects 
on the pharmacokinetic parameters of ATV were assessed. 
Additionally, association studies were performed to test for 
a correlation between metabolizing phenotypes and genetic 
variants. It was observed that carriers of the genotypes A/C 
and C/T in AGTR1 and BDKRB2 had higher area under the 
plasma concentration-time curve values from time 0 to the 
time of the last measurement and from time 0 extrapolated 
to infinity, and lower values of clearance of the fraction dose 
absorbed compared with homozygous carriers (P<0.05). Only 
the C/C genotype of BDKRB2 was associated with the fast 
metabolizer phenotype. These data suggest that AGTR1 and 
BDKRB2 are involved in ATV pharmacokinetics; a novel 
finding that requires confirmation in further studies.
Introduction
The prevalence of chronic degenerative diseases has increased 
in the adult Mexican population (1,2). In Mexico, cardiovas-
cular disease (CVD) was a leading cause of death in 2015 (3), 
while hypercholesterolemia, a major risk factor for CVD, 
was the most prevalent type of dyslipidemia in the Mexican 
population between 2003 and 2005 (4). Statins are choles-
terol-lowering drugs, and in 2012, atorvastatin (ATV) was 
the most frequently prescribed statin in Mexico (5). Within 
liver cells, ATV disrupts cholesterol biosynthesis by blocking 
3-hydroxy-3-methylglutaryl-coenzyme A reductase, which 
reduces the amount of cholesterol released into the blood. As 
a consequence, low-density lipoprotein cholesterol uptake by 
liver cells increases and blood cholesterol levels diminish (6). 
However, in clinical trials of ATV, pharmacokinetic param-
eters including maximum plasma concentration (Cmax), time 
to reach Cmax (Tmax), area under the plasma concentration-time 
curve (AUC) from time 0 to the time of last measurement 
(AUC0-t), AUC from time 0 extrapolated to infinity (AUC0‑∞), 
apparent clearance of the fraction dose absorbed (Cl/F), 
elimination rate constant in the terminal drug phase (Ke) and 
the half-life in the terminal drug phase (T1/2) are variable (7). 
This reflects the underlying variability in the absorption, 
distribution, metabolism and excretion (ADME) processes 
of ATV, which may affect the pharmacological response (8). 
Although in general, genetic factors influence ~30% of varia-
tion in drug disposition and response (9,10), recent results 
have indicated that genetic variability may contribute to 
>90% of the variance in ATV plasma concentrations (11). 
These differences in the ADME characteristics of ATV have 
been attributed to polymorphisms in genes associated with 
drug pharmacokinetics, particularly those encoding enzymes 
and transporters (7,10,11).
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The anti‑inflammatory effect of statins has been investi-
gated (12). The angiotensin II type 1 receptor (AGTR1) blocks 
the angiotensin II pathway and has been associated with the 
development of atherosclerosis (12). In addition, polymor-
phisms in AGTR1 have been associated with muscle toxicity 
in patients treated with statins (13). In addition to AGTR1, 
angiotensinogen (AGT) is part of the renin-angiotensin-aldo-
sterone system (14). An improved response to diuretics has 
been observed in the presence of the AGTR1 A1166C and 
AGT G-6A polymorphisms in African-American women and 
a Chinese population (15,16).
The kallikrein-kinin system is also involved in multiple 
cardiovascular events; it modulates the renin-angiotensin- 
aldosterone system, promotes vasodilation, modulates neovas-
cularization and stimulates the inflammatory response (17). 
Genetic variants in the bradykinin B2 receptor (BDKRB2) 
and endothelial nitric oxide synthase (eNOS) genes have 
been associated with CVD risk (18,19). Notably, the BDKRB2 
C(-58)T polymorphism has been associated with hyperten-
sion in an Asian population; carriers of the C/C genotype had 
an increased risk, whereas carriers of the T/T genotype had 
a decreased risk. However, in Asian heterozygous carriers, 
Americans and Europeans, no association has been identi-
fied (20), though an improved response to enalapril for the 
treatment of hypertension has been observed in individuals 
with the C/C genotype (21).
Although polymorphisms in the AGTR1, AGT and BDKRB2 
genes have been described, there is a lack of studies on their 
frequency and effect on ATV pharmacokinetics. Therefore, 
the present study aimed to: i) Identify novel polymorphic vari-
ants influencing the pharmacokinetic parameters of ATV; and 
ii) associate genotypes with metabolizing phenotypes.
Materials and methods
Design. A randomized clinical study was conducted in 
60 healthy volunteers of Mexican origin to assess the 
bioequivalence of a single oral dose (80 mg) of ATV (coated 
tablets; Pfizer, Inc., New York, NY, USA) (7). The study was 
performed according to the guidelines of the Declaration 
of Helsinki (22), of Tokyo for Good Clinical Practice 
Standards (23), and to Mexican regulations for studies of 
bioavailability and bioequivalence (24). The clinical protocol 
was approved by the Research and Ethics Committee of the 
Clinical and Experimental Pharmacology Center, Ipharma S.A. 
(Monterrey, Mexico), and the pharmacogenetic procedure was 
approved by the Ethics, Research and Biosecurity Committees 
of the University of Monterrey (Monterrey, Mexico). The study 
was registered with the Federal Commission for Protection 
Against Health Risks under code Atorvastatina/A95-10Bis and 
in the Register of Clinical Trials of Australia and New Zealand 
(registration no. ACTRN12614000851662). Written informed 
consent was obtained from all subjects.
Study population. As described in our preliminary pilot 
study (7), a total of 60 healthy male volunteers of Mexican 
origin were included in the study from January 2011 to 
February 2011, with a mean age of 24.01±4.35 years. The 
inclusion criteria were as follows: Non-smoker; 18-45 years 
old; weight, ≥50 kg; body mass index, 20‑26 kg/m2; availability 
to complete the study and normal health status (free from 
disease). Health status was assessed based on physical 
examination, medical history and clinical and biochemical 
tests. Insufficiency in any requirement (abnormal laboratory 
results, drug abuse, ingestion of alcohol 1 week prior to the 
study, prescription or over-the-counter medication prior to 
enrollment and reluctance to complete the study) was reason 
for exclusion from the study. Women were excluded as ATV 
is classified as a pregnancy category X drug (25). All subjects 
were informed of the aims of the study.
Sampling. ATV administration and blood sampling were 
performed as described in the pilot study (7). Briefly, periph-
eral blood (4 ml) was collected in K2EDTA-coated BD 
Vacutainers® (BD Diagnostics, Franklin Lakes, NJ, USA) at 
different time points: Prior to drug administration (time 0) and 
at 17 time points (0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 
12, 24, 36 and 48 h) after drug administration. The plasma was 
used for pharmacokinetic analysis and DNA was isolated from 
blood cells using an alkaline lysis method (26). Genomic DNA 
was quantified by UV absorbance using a Nanodrop 1000 
Spectrophotometer (Thermo Fisher Scientific, Inc., Waltham, 
MA, USA). An absorbance 260/280 ratio between 1.8 and 2 
was considered of adequate quality for subsequent use. The 
DNA concentration was adjusted to 10 ng/µl and stored 
at ‑20˚C until analysis.
Pharmacokinetic analysis. ATV plasma concentrations 
were measured by high-performance liquid chromatography 
tandem mass spectrometry with an Agilent 1100 system 
(Agilent Technologies, Inc., Santa Clara, CA, USA) using a 
method validated by Ipharma S.A. (7,27,28). The Cmax and 
Tmax parameters were obtained from the concentration-time 
data of the plasma. Pharmacokinetic parameters including 
AUC0-t, AUC0‑∞, Cl/F, Ke, and T1/2, were calculated with a 
non-compartmental method (29) using WinNonlin® soft-
ware v5.3 (Pharsight Corp., Mountain View, CA, USA) as 
described in the pilot study (7).
Metabolic phenotype classification. The metabolizer pheno-
types were determined according to the results of a multivariate 
analysis of the combined pharmacokinetic parameters Cmax 
and AUC0-t (7). First, Cmax and AUC0-t were standardized to 
minimize the effect of scale differences, and a distance matrix 
was made from the combined standardized Cmax and AUC0-t 
values. Subsequently, hierarchical cluster analysis (HCA) using 
the Ward linkage method (30) was performed on individual 
Cmax and AUC0-t values. Finally, the interindividual Manhattan 
distances were computed. Minitab 16 software (Minitab Inc., 
State College, PA, USA) was used for standardization and 
HCA.
Pharmacogenetic tests. DNA samples were genotyped 
for the polymorphisms AGT-rs699, AGTR1-rs5186 and 
BDKRB2-rs1799722 using real-time polymerase chain reac-
tion and Taqman® probes (Applied Biosystems; Thermo Fisher 
Scientific, Inc.) according to the manufacturer's protocol. 
Three quality controls thresholds were applied: A genotype 
call rate equal to 1.0, a Hardy-Weinberg equilibrium (HWE) 
test with P>0.05, and a minor allele frequency of >0.01.
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Statistical analysis. The HWE was determined by 
comparing the genotype frequencies with the expected 
values using the maximum likelihood method (31). All 
statistical analysis was performed with SPSS v20 software 
(IBM Corp., Armonk, NY, USA). To assess the effects of 
polymorphisms on the ATV pharmacokinetic parameters, 
comparisons between two and three groups were made. The 
Student's t-test and one-way analysis of variance were used 
for parametric distributions, while Mann-Whitney U and 
Kruskal-Wallis H tests were used for nonparametric distri-
butions. To confirm the contribution of genetic factors to the 
variability of pharmacokinetic parameters, linear regression 
analysis was performed. Possible associations of genotypes 
or combinations of genotypes with phenotypes were evalu-
ated using χ2 and Fisher's exact tests. Linear regression and 
associations were assessed under three different models 
(dominant, over-dominant and recessive) (32). The odds ratio 
(OR) was estimated with a 95% confidence interval (95% 
CI). All P-values were two-tailed. Corrected P-values (Pc) 
were obtained using the Bonferroni correction for exclusion 
of spurious associations. P<0.05 was considered to indicate 
statistical significance.
Results
Metabolic phenotype classification. As reported in our 
previous study (7), the classification of metabolizer phenotypes, 
based on the combination of the Cmax and AUC0-t param-
eters, identified three ATV metabolizer phenotypes: Slow 
metabolizers (30.00%), normal metabolizers (41.66%) and fast 
metabolizers (28.33%). The Cmax and AUC0-t parameters used 
for the classification were significantly different between the 
three phenotypes (7); the parameters were significantly higher 
for the slow phenotype compared with the normal and fast 
phenotypes, and significantly higher for the normal phenotype 
compared with the fast phenotype (P<0.05; Fig. 1). None of the 
subjects reported any side effects (7).
Pharmacogenetic tests. Allele frequencies of the genetic poly-
morphisms were consistent with HWE (P>0.05). All genetic 
polymorphisms satisfied the quality control tests.
Association between genotypes and ATV pharmacokinetics. 
There was no significant effect of the AGT-rs699 poly-
morphism on ATV pharmacokinetic parameters (Table I). 
Conversely, AUC0-t and AUC0‑∞ values were significantly 
higher in individuals with the heterozygous genotype (A/C) 
of the AGTR1-rs5186 polymorphism when compared with the 
C/C genotype (P<0.05). In addition, the AUC0‑∞ of the A/C 
genotype was increased compared with that observed for the 
combination of the homozygous wild-type and homozygous 
variant alleles (A/A+C/C; P<0.05). In heterozygous carriers, 
Cl/F values were significantly lower than those observed for 
homozygous variant allele carriers (C/C) and for the combi-
nation of homozygous alleles (A/A+C/C; P<0.05; Table I and 
Fig. 2A and B).
For BDKRB2-rs1799722, carriers of the heterozygous 
genotype (C/T) were identified to have significantly higher 
values of AUC0-t (P=0.021) and AUC0‑∞ (P=0.023) and lower 
values of Cl/F (P=0.007) compared with those obtained for 
the combination of homozygous alleles (C/C+T/T; Table I and 
Fig. 2C and D).
The linear regression analysis under the over-dominant 
genetic model indicated that the AGTR1-rs5186 polymorphism 
significantly affected the values of T1/2 (adjusted R2=0.053, 
P=0.043); however, on comparison of the means by geno-
type, no significant differences were observed. Similarly, the 
BDKRB2‑rs1799722 polymorphism significantly affected the 
Cl/F values (adjusted R2=0.093, P=0.01; data not shown).
Association between genotypes and metabolizer phenotypes. 
Of the two polymorphisms with an effect on ATV pharma-
cokinetics, BDKRB2-rs1799722 was associated with fast 
metabolism when considering genetic models; association 
analysis using the dominant model identified that the C/C 
Table I. Effect of polymorphisms on the pharmacokinetic parameters of atorvastatin. 
 Genotypes N Cmax (ng/ml) AUC0-t (ng/ml/h) AUC0‑∞ (ng/ml/h) Cl/F (l/h) Ke T1/2 (h)
AGT-rs699 A/A 4 45.72±11.03 109.72±38.89 121.44±43.81 729.06±266.90 0.05±0.02 14.97±9.68
 A/G 29 43.21±21.06 141.98±51.00 159.05±56.37 588.08±279.10 0.07±0.04 12.43±7.99
 G/G 27 51.20±26.65 189.40±11.65 200.34±110.61 516.63±246.52 0.08±0.02 9.22±3.25
 A/A+A/G 33 43.51±20.00 138.07±50.32 154.49±55.82 605.17±277.53 0.07±0.04 12.74±8.09
AGTR1-rs5186 A/A 34 44.14±22.86 155.21±83.44 166.63±81.73 585.92±269.36 0.08±0.03 9.78±5.53
 A/C 21 54.80±23.47 186.44±92.45a 204.55±94.76a 473.67±220.44a 0.06±0.03 13.49±8.12
 C/C 5 33.36±18.79 95.57±43.10 109.28±40.84 810.19±275.81 0.07±0.02 10.72±3.30
 A/A+C/C 39 42.76±22.46 147.56±81.54 159.28±79.71b 614.68±277.11b 0.08±0.03 9.90±5.27
BDKRB2-rs1799722 C/C 24 44.00±27.21 151.53±103.77 163.00±102.00 649.67±316.78 0.09±0.02 8.78±3.27
 C/T 27 51.80±20.93 180.66±78.48c 194.17±77.38d 469.55±168.36e 0.07±0.04 12.64±7.21
 T/T 9 40.40±17.73 128.38±42.26 150.31±66.35 627.71±287.80 0.06±0.02 13.05±9.53
 C/C+T/T 33 43.02±24.76 145.22±91.08 159.54±92.80 643.68±304.85 0.08±0.02 9.94±5.84
Data are presented as the mean ± standard deviation. aP =0.015 (A/C vs. C/C), bP =0.040 (A/A+C/C vs. A/C), cP =0.021 (C/C+T/T vs. C/T), dP =0.023 (C/C+T/T 
vs. C/T), eP =0.007 (C/C+T/T vs. C/T). AGT, AGTR1, angiotensin II type 1 receptor; BDKRB2, bradykinin B2 receptor; Cmax, maximum plasma concentration; 
AUC, area under the plasma concentration-time curve; AUC0-t, AUC from time 0 to the time of last measurement; AUC0‑∞, AUC from time 0 extrapolated to 
infinity; Cl/F, apparent clearance of the fraction dose absorbed; Ke, elimination rate constant in the terminal drug phase; T1/2, half-life in the terminal drug phase. 
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Figure 2. AGTR1 and BDKRB2 genotypes based on atorvastatin pharmacokinetics. (A) Mean values of AUC0-t and AUC0‑∞ for the genotypes and genotype 
combinations of AGTR1-rs5186; (B) mean values of Cl/F for the genotypes and genotype combinations of AGTR1-rs5186; (C) mean values of AUC0-t and 
AUC0‑∞ for the genotypes and genotype combinations of BDKRB2-rs1799722; (D) mean values of Cl/F for the genotypes and genotype combinations of 
BDKRB2-rs1799722. Data are presented as the mean ± standard error. *P<0.05 vs. C/C; #P<0.05 vs. A/C; §P<0.05 and §§P<0.01 vs. C/C+T/T. AGTR1, angio-
tensin II type 1 receptor; BDKRB2, bradykinin B2 receptor; AUC, area under the plasma concentration-time curve; AUC0-t, AUC from time 0 to the time of 
last measurement; AUC0‑∞, AUC from time 0 extrapolated to infinity; Cl/F, apparent clearance of the fraction dose absorbed.
Table II. Association between genotypes and metabolizer phenotypes.
Gene Polymorphism Model OR (95% CI) P‑value Pc‑value
BDKRB2 rs1799722 Dominant (C/C vs. C/T+T/T) C/C: Fast metabolizers  0.014 0.03
   0.47 (0.26-0.83)  
   C/T+T/T: Normal/slow metabolizers  
   1.98 (1.01-3.88)  
BDKRB2 rs1799722 Over-dominant (C/C+T/T vs. C/T) C/C+T/T: Fast metabolizers 0.036 0.07
   0.68 (0.40-0.92)  
   C/T: Normal/slow metabolizers  
   2.27 (0.92-5.60)  
BDKRB2, bradykinin B2 receptor; OR, odds ratio; CI, confidence interval; Pc, Bonferroni‑corrected P‑values. 
Figure 1. Metabolizer phenotypes based on atorvastatin pharmacokinetics. (A) Metabolizer phenotypes based on Cmax values; (B) metabolizer phenotypes 
based on AUC0-t values. Data are presented as the mean ± standard error. *P<0.05 vs. normal; #P<0.05 vs. fast; §P<0.05 vs. slow. Cmax, maximum plasma 
concentration; AUC0-t, area under the plasma concentration-time curve from time 0 to the time of last measurement.
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genotype of BDKRB2-rs1799722 was associated with the fast 
metabolizer phenotype (OR, 0.47; 95% CI, 0.26‑0.83), whereas 
the C/T+T/T combination was associated with the normal 
and slow phenotypes (OR, 1.98; 95% CI, 1.01‑3.88; P=0.014). 
When using the over-dominant model, the C/C+T/T combina-
tion was associated with the fast metabolizer phenotype (OR, 
0.68; 95% CI, 0.40‑0.92) and C/T was associated with the 
normal and slow phenotypes (OR, 2.27; 95% CI, 0.92‑5.60; 
P=0.036). However, following Bonferroni's correction, only 
the associations under the dominant model remained statisti-
cally significant (Pc=0.03; Table II).
Discussion
The pharmacokinetic parameters of ATV, namely Cmax and 
AUC, may vary by >10-fold (7,33). Following analysis of 
pharmacokinetic discrepancies, three major metabolizer 
phenotypes of ATV have been identified in Chinese and 
Mexican populations (7,33). This variation has been associated 
with polymorphisms in genes encoding drug metabolizing 
enzymes and transporters (34). However, differences in 
allele frequencies and their effect on quantitative parameters 
including cholesterol levels, arterial pressure and pharmaco-
kinetic parameters, and associations of genotypes with drug 
metabolism and response have been documented across 
various populations (7,33,35,36).
In the current study, the effect on ATV pharmacoki-
netics of three polymorphic variants in genes related to drug 
metabolism and response were evaluated. AGT-rs699 had no 
significant effect on pharmacokinetic parameters. However, 
to the best of our knowledge, the study is the first to identify 
an effect of AGTR1-rs5186 and BDKRB2-rs1799722 on ATV 
pharmacokinetics.
Heterozygous carriers of rs5186 (A/C) exhibited higher 
AUC0-t and AUC0‑∞ values, while having lower Cl/F values, 
than homozygous carriers (C/C), which thus indicates a dimin-
ished clearance activity and longer permanence of ATV in 
heterozygous carriers. The effect of the AGTR1 polymorphism 
on T1/2 was consistent with this interpretation. This decreased 
clearance and longer exposure to ATV may lead to an improved 
response to drug therapy, or to an adverse effect. By contrast, 
carriers of homozygous genotypes (A/A or C/C) had increased 
clearance, and thus may have a poorer response to treatment. 
However, there was no association between the A/A or C/C 
genotypes with the fast metabolizer phenotype. To the best of 
our knowledge, this is the first report on the influence of rs5186 
on ATV pharmacokinetics, though the rs5186 polymorphism 
has previously been associated with lipid levels (37), and 
ATV, as a statin, has lipid-lowering effects (38). Consistent 
with the present results, the C/C genotype has been related 
to higher levels of triglycerides in a healthy Malayan popula-
tion (37). Additionally, in a case-control study conducted in 
a Northern Indian population, the C/C genotype was associ-
ated with essential hypertension and higher gene expression 
of AGTR1 (39). Regarding the anti-inflammatory effect of 
statins, ATV may affect activation of the angiotensin pathway 
through AGTR1 by attenuating the activity of angiotensin II 
(ANG II), as observed in rats, whereby ATV modulated 
ANG II‑induced expression of inflammatory and fibrogenic 
genes in the liver (40); however there is a lack of data regarding 
the association of AGTR1‑rs5186 with the anti‑inflammatory 
response.
Regarding BDKRB2-rs1799722, significant differences 
in the AUC0-t, AUC0‑∞ and Cl/F parameters were identi-
fied between heterozygous carriers (C/T) and homozygous 
carriers (C/C or T/T). The current results suggest that the 
BDKRB2-rs1799722 polymorphism affects ATV clearance 
activity. This effect was demonstrated by linear regression 
and association analyses under over-dominant and dominant 
models. Notably, it was indicated that the C allele promotes 
fast metabolism, while accumulation of the T allele leads to a 
shift towards slower metabolism. However, the pharmacoki-
netic parameters of the T/T homozygous carriers did not differ 
significantly compared with heterozygous carriers. To the best 
of our knowledge, BDKRB2-rs1799722 has not previously been 
associated with statin metabolism. However, a meta-analysis 
identified that the C allele of rs1799722 increased the risk 
of hypertension in Asian and African-American popula-
tions (20). A pharmacogenetic study conducted in a Brazilian 
population revealed that carriers of the C allele responded to 
Enalapril, an antihypertensive drug that serves as an inhibitor 
of angiotensin-converting enzyme (21). The statins are also 
established for their antihypertensive effects in hypercholes-
terolemic patients (41). Nonetheless, there is a lack of studies 
into the effect of BDKRB2-rs1799722 on the metabolism or 
response of patients to statins.
Although a number of polymorphisms have been suggested 
as candidate responsible for the pharmacokinetic variability of 
ATV, the present study is the first to indicate the involvement 
of AGTR1-rs5186 and BDKRB2-rs1799722. The inclusion of 
these biomarkers in future studies may improve the prediction 
of the pharmacokinetic variability of ATV or decrease the 
number of variants required for prediction (7,11). While the 
current study demonstrated the contribution of genetic poly-
morphisms to ATV pharmacokinetics, there were a number of 
limitations. Firstly, there was a lack of data, such as cholesterol 
levels at one month post-treatment, for complete analysis of 
polymorphism effect on response. Secondly, in some cases the 
number of subjects per genotype was small, and thus associa-
tions may have been lost following correction. To validate the 
results, further studies should be performed in a larger popula-
tion. In addition, the influence of other genes may explain the 
lack of association with the slow metabolizer phenotype.
In conclusion, a significant effect of AGTR1-rs5186 and 
BDKRB2-rs1799722 on ATV pharmacokinetics was detected. 
The present findings suggest that the A/C genotype of 
AGTR1-rs5186 is associated with slow ATV metabolism, while 
the C/C or A/A+C/C genotypes are associated with fast metab-
olism. Additionally, the C/T genotype of BDKRB2-rs1799722 
may be associated with the slow metabolizer phenotype, while 
the homozygous genotypes may be associated with the fast 
metabolizer phenotype. These novel findings increase the panel 
of potential genetic biomarkers associated with ATV metabo-
lism, and should be verified in future pharmacogenetic studies 
in larger populations with different genetic backgrounds.
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